Orion Biotechnology is a clinical stage company that is unlocking the market potential of a very large group of promising drug targets – called G Protein Cell Receptors (GPCRs) – with a new class of precision engineered drugs enabled by the company’s proprietary discovery platform. Orion is leveraging its platform to grow a pipeline of highly potent, next generation therapeutics for cancer and other serious diseases.
